Organon & Co. (NYSE:OGN) was upgraded by analysts at Barclays PLC to a "strong sell" rating.
Organon & Co. (NYSE:OGN) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $7.50 price target on the stock.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US